Paramesu Biotech Limited - Due diligence report

A 360° intelligence report on Paramesu Biotech Limited: trust score, financial health, credit view, compliance, directors, growth and distre…

2011-09-07 Devarapalli, Andhra Pradesh Active Unlisted Active Compliant
Share
Connect MCP
PB Paramesu Biotech Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Paramesu Biotech Limited — 360° Intelligence Report

Generated from MCA filings & public records
76/100
Trust Score
Low Risk

Paramesu Biotech Limited is assessed as Low Risk with a Trust Score of 76/100. Paramesu Biotech Limited is an active public limited indian non-government company incorporated in 2011, operating in the Chemicals and Materials sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 31 Jul 2026 from the latest processed filings. Paramesu Biotech Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
81/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
30/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 60/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.
  • Externally credit-rated (BBB).

Charges position: 4 open (494.38 cr) · 3 satisfied (65.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited2 48.0 cr
Indian Bank4 48.0 cr
Others1 48.0 cr
Compliance Score: 81/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 1 court forum(s).
  • 3 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 30/100
NameDIN / PANDesignationAppointedTenureDIN status
SANYUKTA JODHANI 01234567 Director 01/04/2018 6 yrs Approved
LAKSHMIPATHI REDDY GARACHETLA 01234567 Director 01/04/2018 6 yrs Approved
VENKATESWARLU USURUPATI 01234567 Director 01/04/2018 6 yrs Approved
Yedla Maithri 01234567 Director 01/04/2018 6 yrs Approved
Satya Suresh Veeravilli 01234567 Director 01/04/2018 6 yrs Approved
MANISWETHA TETAI 01234567 Director 01/04/2018 6 yrs Approved
ANANDA SWAROOP ADAVANI 01234567 Director 01/04/2018 6 yrs Approved
Amulya Dasari 01234567 Director 01/04/2018 6 yrs Approved
Satya Suresh Veeravilli 01234567 Director 01/04/2018 6 yrs Approved
  • 9 directors on the board.
  • VENKATESWARLU USURUPATI has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • 10 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Unimark Business Solutions Private Limited
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 5 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Unimark Business Solutions Private Limited Holding Company 74.00%

Key managerial personnel: Satya Suresh Veeravilli (Whole-time director) · MANISWETHA TETAI (Whole-time director) · ANANDA SWAROOP ADAVANI (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 14+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
6 director exits within 2 years.
4 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment71/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 494.38 cr already registered.
  • Compliance record supports lending.
Investor view85/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
19 Jul 2025
Charge created
Hdfc Bank Limited - 255.00 cr
11 Jun 2025
Charge satisfied
Others
06 Nov 2024
Director appointed
Satya Suresh Veeravilli (Cfo)
04 Nov 2024
Director appointed
Satya Suresh Veeravilli (Whole-time director)
Director ceased
Satya Suresh Veeravilli
22 Oct 2024
Director ceased
Yedla Maithri
04 Oct 2024
Director appointed
Yedla Maithri (Director)
18 Sep 2024
Last AGM held
Annual general meeting
17 Sep 2024
Director ceased
PRADIPTA KUMAR SAHOO
Director ceased
LAKSHMIPATHI REDDY GARACHETLA
Director ceased
VENKATESWARLU USURUPATI
05 Sep 2024
Charge created
Others - 25.00 cr
27 Aug 2024
Director appointed
LAKSHMIPATHI REDDY GARACHETLA (Director)
Director appointed
VENKATESWARLU USURUPATI (Director)
13 Aug 2024
Director ceased
MANISWETHA TETAI
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
9 active director(s) / partner(s); review board churn before relying on management continuity.
3 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BBB from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Kiri Industries L24231GJ1998PLC034094 Ahmedabad, Gujarat, India
Baidyanath U24233WB1947PTC015374 Kolkata, West Bengal, India
Kokuyocamlin L24223MH1946PLC005434 Mumbai, Maharashtra, India
Gramercy Trade Industries Private Limited U24112PN2021PTC205986 Pune, Maharashtra, India
Eris Therapeutics Limited U24230GJ2021PLC123519 Ahmadabad City, Gujarat, India
Samilabs U68100KA1991PLC011880 Bangalore, Karnataka, India
Windlas L74899UR2001PLC033407 Dehradun, Uttarakhand, India
Neogenchem L24200MH1989PLC050919 Thane, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Paramesu Biotech Limited before audits and certifications: compliance score 81/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Paramesu Biotech Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Paramesu Biotech Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Paramesu Biotech Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Paramesu Biotech Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Paramesu Biotech Limited an active company?

Paramesu Biotech Limited has MCA status “Active” with a compliance score of 81/100 (Low Risk).

Is Paramesu Biotech Limited financially healthy?

Paramesu Biotech Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Paramesu Biotech Limited?

Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Paramesu Biotech Limited?

The ultimate holding entity is Unimark Business Solutions Private Limited. 9 active director(s) are on record.

Does Paramesu Biotech Limited have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Paramesu Biotech Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 81/100 (Low Risk).

Is it risky to lend to Paramesu Biotech Limited?

Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.